[(3,3'-dihydroxy-2,2'-bipyridine)Re(CO)3Cl] | 524010-04-6

• 英文名称: [(3,3'-dihydroxy-2,2'-bipyridine)Re(CO)3Cl]
• 英文别名: [Re(3,3′-dihydroxy-2,2′-bipyridine)Cl(CO)₃]
• CAS: 524010-04-6
• 化学式: C₁₃H₈ClN₂O₅Re
• 分子量: 493.877
• InChiKey: BFRUMFJUYUKCOE-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为反应物：
  描述：

  [(3,3'-dihydroxy-2,2'-bipyridine)Re(CO)3Cl] 在 氢氧化钾 作用下， 以 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Optical properties of (3,3′-dihydroxy-2,2′-bipyridine) tricarbonyl-rhenium(I) chloride. Absorption and emission spectra

  摘要：

  The complex [bipy(OH)(2)]Re(I)(CO)(3)Cl with bipy(OH)(2) = 3,3'-dihydroxy-2,2'-bipyridine has been prepared and characterized by elemental analysis, ESI MS and UV-Vis spectroscopy. The complex shows a yellow emission at lambda(max) = 582 nm which originates from the lowest-energy bipy(OH)(2) intraligand (IL) triplet. The compound undergoes a reversible deprotonation to [(bipyO(2))Re(I)(CO)(3)Cl](2-) which is not luminescent under ambient conditions. (C) 2002 Elsevier Science B.V. All rights reserved.

  DOI：

  10.1016/s0020-1693(02)01175-1
• 作为产物：
  描述：

  在 氢气 作用下， 以 not given 为溶剂， 生成 [(3,3'-dihydroxy-2,2'-bipyridine)Re(CO)3Cl]
  参考文献：
  名称：

  Optical properties of (3,3′-dihydroxy-2,2′-bipyridine) tricarbonyl-rhenium(I) chloride. Absorption and emission spectra

  摘要：

  The complex [bipy(OH)(2)]Re(I)(CO)(3)Cl with bipy(OH)(2) = 3,3'-dihydroxy-2,2'-bipyridine has been prepared and characterized by elemental analysis, ESI MS and UV-Vis spectroscopy. The complex shows a yellow emission at lambda(max) = 582 nm which originates from the lowest-energy bipy(OH)(2) intraligand (IL) triplet. The compound undergoes a reversible deprotonation to [(bipyO(2))Re(I)(CO)(3)Cl](2-) which is not luminescent under ambient conditions. (C) 2002 Elsevier Science B.V. All rights reserved.

  DOI：

  10.1016/s0020-1693(02)01175-1

文献信息

• Re ^I Tricarbonyl Complexes as Coordinate Covalent Inhibitors for the SARS‐CoV‐2 Main Cysteine Protease
  作者：Johannes Karges、Mark Kalaj、Milan Gembicky、Seth M. Cohen

  DOI：10.1002/anie.202016768

  日期：2021.5.3

  syndrome—coronavirus 2 (SARS‐CoV‐2) has impacted the quality of life and cost hundreds‐of‐thousands of lives worldwide. Based on its global spread and mortality, there is an urgent need for novel treatments which can combat this disease. To date, the 3‐chymotrypsin‐like protease (3CLpro), which is also known as the main protease, is considered among the most important pharmacological targets. The vast majority

  自爆发以来，严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 影响了生活质量，并导致全世界数十万人丧生。鉴于其在全球的传播和死亡率，迫切需要能够对抗这种疾病的新疗法。迄今为止，3-胰凝乳蛋白酶样蛋白酶（3CL pro ）也被称为主要蛋白酶，被认为是最重要的药理学靶点之一。绝大多数研究的 3CL前体抑制剂都是有机非共价结合剂。在此，建议使用无机配位共价结合剂来减弱蛋白酶的活性。 Re 三羰基复合物被鉴定为 3CL pro的协调共价酶抑制。初步研究表明 3CL pro对几种人类蛋白酶具有选择性抑制作用。这项研究首次展示了金属配合物作为 3CL半胱氨酸蛋白酶抑制剂的例子。